Continuing research efforts on Talecris Biotherapeutics Albumin Products include:
 |
 |
Identifying emerging pathogens
|
|
Continuing the rigorous scientific evaluation of the pathogen safety profile
|
|
Investigating new techniques for pathogen removal and inactivation
|
|
Talecris Biotherapeutics' pathogen safety and research groups continue to explore virus reduction methods targeted at all known classes of viruses to anticipate currently unknown pathogens. These steps will ensure a safe and reliable supply of albumin for our customers.
|
Validated WNV Clearance Steps
|
|
Process Steps
|
Reduction Factor (log10)
|
|
Precipitation/acetone suspension
|
≥6.0
|
|
Pasteurization (5% Albumin)
|
≥7.4
|
|
Pasteurization (20%/25% Albumin)
|
≥6.7
|
The ongoing research conducted by Talecris Biotherapeutics helps alleviate concerns over pathogenic prion proteins1
and assures both physicians and patients that Talecris Biotherapeutics Albumin Products continue to be free of viral contamination.
References:
| 1. |
|
Lee DC, Stenland CJ, Miller JLC, et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion. 2001;41:449-455.
|
|